Hospital systems and academic medical centers have been reaching out to BAMF Health.
“They’re eager to be a part of developing the next imaging, the next therapy drugs and want to have the cutting-edge offerings for their patients as well.”
BAMF RadioNexus fills the need launching a nationwide clinical trials platform. Dan Rogers is Director of Clinical Trials Platform.
“These clinical trials are what help us to determine are these drugs safe and effective at treating things like cancer.”
Rogers says BAMF has the infrastructure and scientific expertise to conduct complex clinical trials. BAMF is a leader in radiopharmaceuticals. One example is radionuclide therapy. A process of injecting a patient with radioactive isotopes attached to a targeting molecule that seeks and destroys cancer.
So far, one national health system has signed on with RadioNexus. Other centers will partner within the next six months.
As the federal government pulls back National Cancer Institute research funding, RadioNexus offers a no cost option for clinical trial partners.
“With some centers that have high reliance historically on N.C.I. funding, I think they are driving towards bring on a more industry sponsored program to essentially make ends meet.”
For all parties, bringing new drugs and therapies to market faster is the goal.
